Research Sample bioBank
Heart Failure Clinical Research Samples
Discovery Life Sciences provides the highest quality Heart Failure Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Heart Failure Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
|Product ID||Sample||Origin||Matrix||Vial (ml)||Quantity||Price||Age||Gender||Ethnicity||Storage Temp||Sample Date||Test 1||Test Data 1||Detail 1||Test 2||Test Data 2||Detail 2||Test 3||Test Data 3||Detail 3||Product|
|Blood Type||Co-morbidities||Consent Status Date||Current Medications||Diagnosis||Height||Weight||Is Pregnant||Menopausal Status||Smoking Notes||Symptoms||Clinical Diagnosis||Comorbidities | Treatment of Comorbidities||ECG | Heart||Abbott Architect | CMIA | Chemiflex||Treatment of Comorbidities||X-Ray | Chest|
|BBS0000-A0900108476090519DD||Heart Failure||Serum||1.00||1.00||$200.00||59 Y||Female||Non-Hispanic||<-70C||05-Sep-19||ECG | Heart||140/90||Laboratory results||C-reactive protein (CRP) - 30.11 mg/l; Creatine Kinase - MB (CPK-MB) - 19 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 171.7 pg/ml||5-Sep-19||HIV I & II | HBV | HCV Results||Negative||$200.00||Unknown||N/A||164 cm 72 kg||Ischemic heart disease: cardiosclerosis, Heart failure, grade I. Functional class, grade II (NYHA).||Essential hypertension, grade II 02/01/2014|
Enap-H (Enalaprilum, Hydrochlorothiazide) 02/01/2014
|BBS0000-A0900108544090519DD||Heart Failure||Serum||1.00||1.00||$200.00||68 Y||Female||Non-Hispanic||<-70C||05-Sep-19||ECG | Heart||130/90||Fibrosclerotic valve changes, expansion of the right ventricle, diastolic dysfunction.||Laboratory results||C-reactive protein (CRP) -2.55 mg/l; Creatine Kinase-MB (CPK-MB) - 13 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 376.7 pg/ml||5-Sep-19||HIV I & II | HBV | HCV Results||Negative||$200.00||Unknown||Spironolactonum 25 mg, Torasemide 10 mg, Bisoprolol 5 mg, Valsartan 160 mg||165 cm 71 kg||Ischemic heart disease:cardiosclerosis. Mitral valve insufficiency, stage I. Atrial fibrillation. Arterial hypertension, grade II, stage I-II, risk II. Moderate myocardial hypertrophy. Heart failure, grade I. Functional class, grade II (NYHA).||Coronary heart disease with persistent atrial fibrillation. 01/01/2016, Hypertension, stage II 01/01/2010, Chronic pancreatitis in remission 01/01/2008|
Bisoprolol 01/01/2017, Difors (Valsartan, Amlodipine ) 01/01/2017
|Sinus rhythm regular, signs of enlargement of the left ventricle.|
Paroxysmal tachyarrhythmia with a reduced ejection fraction. Systolic dysfunction of the left ventricle.
Compared with echocardiography from 3/21/2016 without significant dynamics.
|BBS0000-A0900108547090319DD||Heart Failure||Serum||1.00||1.00||$200.00||78 Y||Female||Non-Hispanic||<-70C||03-Sep-19||ECG | Heart||130/80||Aorta-3.2; Aortic valve-regurgitation (+); Left atrium-3.3; Left ventricle-4.5; Walls-1.0; Interventricular septum-1.3; EF-45%.||Laboratory results||C-reactive protein (CRP) -2.7 mg/l; Creatine Kinase-MB (CPK-MB) - 9 U/l; Troponin I <0.1ng / ml; NT-proBNP - 6053 pg/ml||3-Sep-19||HIV I & II | HBV | HCV Results||Negative||$200.00||Unknown||Ksarelto 20 mg||165 cm 82 kg||Pulmonary embolism. Heart failure, grade IIA. Functional class III (NYHA).||Essential hypertension 01/01/2006, Myocardial infarction Phlebothrombosis|
Plavix (Clopidogrel) 08/30/2019, Atorvacor (Atorvastatinum) 08/15/2019, Pantasun (PantÐ¾prazole) 08/15/2019, Diocor (Valsartan, Hidrochlorothiazide) 08/15/2015
|The sinus rhythm is correct. Heart rate 62 beats per minute. Signs of acute anterior septal myocardial infarction.|
|BBS0000-AI900090930083019DD||Heart Failure||United States||Serum||1.25||1.00||$75.00||79 Y||Male||Non-Hispanic||<-70C||30-Aug-19||Diagnosis||Congestive Heart Failure stage 4 (CHF)||$75.00||Unknown||397 pg/mL|
|BBS0000-AI900341749100519DD||Heart Failure||United States||Serum||1.00||1.00||$75.00||43 Y||Male||Non-Hispanic||<-70C||05-Oct-19||Diagnosis||Congestive Heart Failure stage 2 (CHF)||$75.00||Unknown|
|BBS0000-AI900401022042920DD||Heart Failure||United States||Serum||1.00||1.00||$75.00||71 Y||Male||Non-Hispanic||<-70C||29-Apr-20||Abbott Architect | CMIA | Chemiflex||4,080||BNP||$75.00||Unknown|
|BBS0000-AI900427299092220DD||Heart Failure||United States||Serum||1.00||1.00||$75.00||54 Y||Female||Non-Hispanic||<-70C||22-Sep-20||Diagnosis||CHF Stage 3||Abbott Architect | CMIA | Chemiflex||675 pg/mL||BNP||$75.00||Unknown|
|BBS0000-G2900433673110518D1||Heart Failure||Ukraine||Serum||13.00||1.00||$200.00||66 Y||Male||Non-Hispanic||<-70C||05-Nov-18||ECG | Heart||145/90||Sinus rhythm regular, heart rate 60 Signs of preinfarction cardiosclerosis of the anterior septum sections from the apex and side wall 09/06/2019||Laboratory results||C-reactive protein (CRP) - 1.06 mg/l; Creatine Kinase-MB (CPK-MB) - 14 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 132.6 pg/ml||6-Sep-19||HIV I & II | HBV | HCV Results||Negative||2019-09-06||$200.00||Unknown||Chronic cerebrovascular accident 01/01/2017, Chronic gastroduodenitis 01/01/2010, Coronary artery bypass grafting-3; Mammary coronary bypass-1 01/16/2018||2019-09-06||Co-Prenesa (Perindopril, Indapamide) 4/1.25 mg, Carvedilol 12.5 mg, Torasemide 10 mg||Ischemic heart disease:Exertional angina, Functional class, grade II-III. Postinfarction cardiosclerosis (2017), Aortocoronary bypass-3; Interventricular septum-1 (1/16/2018). Aortic malformation, stage I-II; Mitral valve insufficiency, stage I-II; Arterial hypertension,grade III, stage II, risk IV. Heart failure, grade IIA. Functional class, grade II (NYHA).||65.75||180||False||Non-Smoker||Pain in the heart, shortness of breath when walking, weakness, dizziness, Cor-tons is weakened, rhythmic as extrasystoles, emphasis II tone on the aorta, heart rate 68, moderate swelling of the legs.||Systolic function persists. Mitral valve insufficiency, grade II. Hypertrophy of the interventricular septum. 9/6/2019|
|Lira (Citicoline), Neurotropine (Mexidol), Nolpaza (Pantoprazolum)|
|BBS0000-G2900433674100518D1||Heart Failure||Ukraine||Serum||13.00||1.00||$200.00||61 Y||Female||Non-Hispanic||<-70C||05-Oct-18||ECG | Heart||150/90||Sinus rhythm irregular. Deviation of the electrical axis of the heart to the left, single atrial extrasystoles 09/06/2019||Laboratory results||C-reactive protein (CRP) - 0.82 mg/l; Creatine Kinase-MB (CPK-MB) - 11 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 36.63 pg/ml||6-Sep-19||HIV I & II | HBV | HCV Results||Negative||2019-09-06||$200.00||Unknown||Chronic cholecystopancreatitis 01/01/2008, Arterial hypertension 01/01/2009||2019-09-06||Trifas (Torasemide) 5 mg, Lisinopril 20 mg, Carvedilol 25 mg||Arterial hypertension, grade II, stage II, risk II; Hypertensive retinal angiopathy in both eyes; Dysmetabolic cardiomyopathy; Heart failure, grade I. Functional class, grade I (NYHA).||64.57||180||False||Postmenopausal||Non-Smoker||Shortness of breath during physical exertion, interruptions in the work of the heart, Cor-tons arrhythmic, emphasis II tone on the aorta, swelling of the legs.||Systolic metabolic dysfunction of the left ventricle persists. The wall of the left ventricle is not thickened.|
|Trifas (Torasemide), Lisinopril, Magnicor (com drug: acetylsalicylic acid, magnesium hydroxide), Atorvacor (Atorvastatinum)||The heart is enlarged to the left, the lungs are clean, the roots are dense, and the broncho-vascular pattern is strengthened. |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.